Novo Nordisk has announced the availability of Wegovy® (semaglutide 2.4 mg) in Malaysia, offering a new treatment option for adults living with obesity or overweight with at least one weight-related comorbidity. The launch comes at a critical time, as recent findings from the National Health and Morbidity Survey (NHMS) 2023 reveal that nearly 54.4% of Malaysian adults are classified as living with overweight or obesity.
Obesity is increasingly recognised as a chronic disease rather than a lifestyle choice, and is associated with more than 200 potential health complications, including type 2 diabetes, cardiovascular disease, hypertension and sleep apnoea. These conditions significantly affect both life expectancy and quality of life.
A Medical Approach to Weight Management
Wegovy® is a once-weekly injectable medication that contains semaglutide, a GLP-1 receptor agonist that mimics a naturally occurring hormone released by the gut after eating. The medication works by targeting areas of the brain that regulate appetite and cravings, helping individuals feel fuller for longer and reduce food intake.
The treatment is indicated as an adjunct to a reduced-calorie diet and increased physical activity for adults with a Body Mass Index (BMI) of ≥30 kg/m², or ≥27 kg/m² in the presence of weight-related conditions such as dysglycaemia, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
Clinical data shows that Wegovy® can deliver weight loss of 20% or more in people living with obesity. Importantly, studies indicate that treatment with semaglutide results in a greater reduction in fat mass than lean body mass, supporting healthier, higher-quality weight loss.
Redefining Obesity Care in Malaysia
Dr. Praful Chakkarwar, General Manager of Novo Nordisk Malaysia, described the introduction of Wegovy® as a significant milestone for the country’s healthcare landscape.
“Today marks a pivotal moment in our commitment to transforming obesity care in Malaysia,” he said. “With Wegovy®, we are introducing an effective medical treatment that supports patients on their health journeys. This goes beyond medication — it is part of a broader, long-term strategy that includes local clinical research, partnerships, community education and public platforms such as Truth About Weight.”
Addressing Stigma and Misconceptions
Healthcare experts emphasise that obesity is a complex condition influenced by biological, behavioural and environmental factors, and not simply a matter of willpower.
.jpg)
Professor Dr. Rohana Abdul Ghani, Consultant Endocrinologist and President of the Malaysian Obesity Society (MYOS), highlighted the emotional and social burden faced by individuals living with obesity.
“Obesity is often misunderstood, leading to stigma and self-blame,” she said. “These emotional barriers can make effective weight management even more challenging. A holistic approach — combining medical therapy, education, empathy and multidisciplinary care — is essential to support sustained health improvements.”
Emeritus Professor Dr. Chan Siew Pheng, Honorary Consultant Endocrinologist, added that obesity management requires collaboration across multiple healthcare disciplines.
“Weight loss triggers metabolic adaptations that often lead to weight regain, reinforcing the need for long-term, personalised care,” she explained. “By integrating medication with tailored dietary, physical activity and behavioural interventions, we can significantly improve patient outcomes.”
The Cardiovascular Connection
Dato’ Sri Dr. Azhari Rosman, Senior Consultant Cardiologist, stressed the link between obesity and heart disease.
“The relationship between obesity and cardiovascular disease is well established,” he said. “Effective obesity management is crucial to improving overall health outcomes and reducing long-term cardiovascular risk.”
Looking Ahead
With the introduction of Wegovy®, Novo Nordisk Malaysia aims to support individuals living with obesity through a more comprehensive, science-based approach to care. The company reaffirmed its commitment to working alongside healthcare professionals, policymakers and communities to address chronic diseases and promote healthier futures for Malaysians.